CLN3 and Blindness: The relative lack of visual impairment in all CLN3-deficient mice contrasts with human juvenile NCL where degenerating vision is the lead symptom, and progression to blindness tends to be rapid, although disease does not tend to become apparent until later childhood around 5–10 years of age.